ASX:BXN Bioxyne (BXN) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Bioxyne Stock (ASX:BXN) 30 days 90 days 365 days Advanced Chart Get Bioxyne alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume174,489 shsAverage VolumeN/AMarket CapitalizationA$96.31 millionP/E RatioN/ADividend Yield2.51%Price TargetN/AConsensus RatingN/A Company OverviewBioxyne Limited, a life sciences and consumer health products company, manufactures and distributes consumer health products, patented probiotics, health supplements, therapeutic goods, and alternative medicines in the United Kingdom, Japan, Europe, and Australia. The company manufactures, commercializes, and distributes plant-based wellness products and supplements, including cannabinoids, cannabis extracts, vitamins, manuka honey, skin care products, and mushroom complexes. It develops various functional food products, such as ingredients; and lactobacillus fermentum VRI-003 for over-the counter gut health immune supplement products. The company also provides product research and development services, and telemedicine services. In addition, it operates BLS Clinics, a telehealth platform. The company provides its products online, as well as through wholesale and direct sales in the United States and Asia. Bioxyne Limited was incorporated in 1998 and is headquartered in Sydney, Australia.Read More… Receive BXN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bioxyne and its competitors with MarketBeat's FREE daily newsletter. Email Address BXN Stock News HeadlinesBioxyne Limited Releases Business Update and Progress ReportJune 19, 2025 | tipranks.comBioxyne Limited Expands into German Cannabis Market with €3.2 Million AgreementJune 17, 2025 | tipranks.comA new rule goes live in July — and the banks are quietly cashing inA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big Banks have found a way to use a new asset as if it were cash. Not stocks. Not bonds. Not even the U.S. dollar. They now trust this asset more than the traditional financial system itself. | American Alternative (Ad)Bioxyne Limited Strengthens Advisory Board with Cannabis ExpertApril 2, 2025 | tipranks.comBioxyne Secures $7M Exclusive Manufacturing Deal with NectarTekApril 2, 2025 | tipranks.comBioxyne Limited Achieves Record Q2 Results, Plans Expansion into EuropeJanuary 27, 2025 | tipranks.comBioxyne Limited Announces Cessation of SecuritiesDecember 19, 2024 | tipranks.comBioxyne Limited Director’s Interest UpdateDecember 19, 2024 | tipranks.comSee More Headlines Industry, Sector and Symbol Stock ExchangeASX SectorConsumer Defensive Industry Packaged Foods Sub-IndustryN/A Current SymbolASX:BXN CIKN/A Webwww.bioxyne.com Phone61 2 9078 8180FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)A($0.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-A$12.80 million Net Margins-142.90% Pretax MarginN/A Return on Equity-409.92% Return on Assets-5.80% Debt Debt-to-Equity Ratio18.68 Current Ratio1.92 Quick Ratio2.30 Sales & Book Value Annual SalesA$9.64 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow4.75 Book ValueA$0.00 per share Price / BookN/AMiscellaneous Outstanding Shares2,050,000,000Free FloatN/AMarket CapA$96.31 million OptionableNot Optionable Beta0.78 20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free Report This page (ASX:BXN) was last updated on 6/30/2025 by MarketBeat.com Staff From Our Partners3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredIsrael-Iran WAR Could Destroy Trump's PresidencyThe missiles are already flying. Israel and Iran are now in direct military conflict — and this couldn't ha...American Alternative | SponsoredWhy Is President Trump Fast-Tracking These Companies?Forget about AI… There's a hot new trend on Wall Street… And it's all thanks to President Trump. His ...InvestorPlace | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | Sponsored“Trump’s 24-Hour Profit Windows” revealedTrading legend Larry Benedict has discovered a repeating surge of $240 billion (and more)... Flowing into a...Brownstone Research | Sponsored379 passengers walked away from thisElon Musk just wrote a $51 million check to back this material’s next phase… Because it’s not just saving l...True Market Insiders | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bioxyne Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Bioxyne With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
